YBL-015 / Y-Biologics, IntoCell - LARVOL DELTA

ABL Bio returns IntoCell ADC technology amid patent disclosure concerns (Chosun Biz) - "This decision was made after a recent internal monitoring process revealed that a patent similar in structure to this platform technology was publicly disclosed in China...Y-Biologics clarified through its website the previous day that 'the termination of the ADC platform contract with IntoCell is entirely unrelated to the substances jointly developed by Y-Biologics and IntoCell.' The jointly developed anti-B7-H3 ADC candidate substance 'YBL-015' is a form that combines Y-Biologics' antibody with IntoCell's Opas linker technology and a variant of duocarmycin, indicating that it is an entirely separate technology from the problematic Nexatecan. YBL-015 has already completed patent registration in the United States, and registration examinations are underway in other countries. "

Patent • Breast Cancer • Lung Cancer • Prostate Cancer

Y-Biologics secures patent rights for B7H3 antibody in Korea and Japan…’Accelerates development of ADC new drugs’ [Google translation] (Pharm News) - "Y-Biologics...announced on the 13th that it has completed domestic patent registration for an antibody against B7H3, which is attracting attention as a new target for solid cancer treatment...This patented B7H3 antibody is the core material of the antibody drug conjugate (ADC) 'YBL-015' that is being jointly developed with Intucell."

Patent • Oncology